Although the cumulative success rate for new agents for advanced NSCLC is lower than the industry-estimated rate, clinical trial success has been substantially increased by biomarker- and receptor-targeted therapies.
Health-related quality of life assessment in randomized clinical trials in small cell lung cancer provides added information in studies where the treatment arms do not differ in terms of efficacy.
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two drugs already in use in laboratory and animal studies.
Treating mesothelioma with radiation before surgery resulted in a 3-year survival rate that was more than double compared with that of treating with surgery first, according to new research.
Supplementation with antioxidants markedly increases tumor cell proliferation and tumor growth in mice, researchers found.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|